▲ S&P 500 + | ▲ Stock Advisor + Join The Motley Fool

Accessibility Log In Help

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Recent Articles by Brian Orelli, PhD

GettyImages-1327624070

May 20, 2022 by Brian Orelli, PhD

This Biotech Stock Could See a Huge Boom

This biotech company is showing early promise.

medical professional smiles while at desk with laptop

Apr 6, 2022 by Brian Orelli, PhD, Rachel Warren, and Sanmeet Deo

80% of Physicians Use This Platform, and Its Stock Could Benefit

By catering to the needs of medical professionals, Doximity could deliver in a big way.

medical technology concept

Apr 6, 2022 by Brian Orelli, PhD

10 Exciting Innovations Coming From Google Health

Cutting-edge technology meets traditional healthcare.

GettyImages-stockcrashwoman

Feb 23, 2022 by Brian Orelli, PhD

Why Biotech Stocks Fall After Positive Clinical Trials

Positive clinical results should be a good thing, right?

GettyImages-microscope

Feb 23, 2022 by Brian Orelli, PhD

Should Biotech Investors Hold Out Hope After a Failed Clinical Trial?

What happens after a trial's results are negative -- or positive?

Feb 23, 2022 by Brian Orelli, PhD

Investors: This Is the Gold Standard of Biotech Trials

Trial design may matter more than you think.

GettyImages-1345289043

Feb 22, 2022 by Brian Orelli, PhD, Sanmeet Deo, and Meilin Quinn

Take Pfizer's $50 Billion Covid Payday With a Grain of Salt

Pfizer's foreseeable future looks strong.

Feb 22, 2022 by Brian Orelli, PhD

How Biotech Companies Can Overcome the “Placebo Effect”

Do some drug trial participants see improvements just because they're told they might?

GettyImages-healthcare

Feb 22, 2022 by Brian Orelli, PhD

One Risk-Reward Profile Investors Should Watch in Biotech Trials

Author Dr. Frank David breaks down what investors should look for in trial design.

GettyImages-1256323645

Feb 16, 2022 by Brian Orelli, PhD

Inside Gilead's Lackluster $7.2 Billion Q4 Earnings

Why are investors unenthused with the biotech giant's earnings report?

GettyImages-1319551550(1)

Feb 15, 2022 by Brian Orelli, PhD and Keith Speights

Novavax Investors Can Finally Breathe a Sigh of Relief

Novavax's milestone means investors can now exhale.

GettyImages-1302270618

Feb 15, 2022 by Brian Orelli, PhD

3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch

Is it time to buy a basket of biotech stocks?

GettyImages-1294339670

Feb 14, 2022 by Brian Orelli, PhD and Keith Speights

Tracking Gilead's 4 Big Stories and a Lawsuit in 2022

How will the cost of a settlement affect Gilead's profits over the foreseeable future?

GettyImages-1293772875

Feb 9, 2022 by Brian Orelli, PhD and Keith Speights

2 Exciting Trends That Could Shape Healthcare's Future

These underappreciated opportunities in healthcare are worth a closer look.

doctor and patient 2

Nov 30, 2021 by Brian Orelli, PhD and Keith Speights

Cathie Wood Likes Fate Therapeutics, Should You?

The biotech has an interesting pipeline, but it's all early stage products.

Doctor patient roche biogen

Nov 27, 2021 by Brian Orelli, PhD and Keith Speights

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

The Swiss pharma needs to get its drug approved first.

FDA

Nov 27, 2021 by Brian Orelli, PhD and Keith Speights

Who Would Be the Best FDA Commissioner for Biotech Investors?

Robert Califf got the nod, but current acting commissioner Janet Woodcock would have made a fine choice too.

Shocked investor

Nov 27, 2021 by Brian Orelli, PhD and Keith Speights

Vaxxinity Has a Rough Public Debut

Investors have trouble valuing the biotech's IPO.

mental health doctor

Nov 27, 2021 by Brian Orelli, PhD and Keith Speights

Were Compass Pathways' Clinical Trial Results Really That Bad?

The biotech was priced for perfection; its data wasn't.

Doctor patient Covid test

Nov 27, 2021 by Brian Orelli, PhD and Keith Speights

Is Fulgent Genetics Undervalued?

Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services